The debt is in the form of a secured loan, secured by Concert's assets, excluding intellectual property, and bearing interest at a calculated prime-based variable rate currently at 8.55%.
Concert said the full amount of the loan was funded upon closing. The loan will mature on 1 June 2021.
Payments under the loan are interest-only for a period of 18 months, followed by equal monthly installments of principal and interest for 30 months thereafter.
In addition, Concert has an option under the terms of the loan to pay off the loan within six months with a 50% reduction in the end of term charge and without a prepayment penalty following the closing of the Vertex transaction.
In connection with the debt financing, Concert issued Hercules a warrant to purchase up to 61,273 of Concert's common shares at an exercise price of USD 12.24 per share.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs.
The company's approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems disorders.
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial